Geng Juan, Lei Yan-Rong, Pei Sheng-Guang
Department of Medical Records and Statistics, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, China.
Department of Oncology, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, China.
J Huazhong Univ Sci Technolog Med Sci. 2017 Dec;37(6):965-973. doi: 10.1007/s11596-017-1835-4. Epub 2017 Dec 21.
In order to provide evidence for evidence-based medicine in the treatment and prognosis of laryngeal cancer in China, the meta-analysis electronically retrieved the case-control studies published in China about the Survivin expression and its association with clinical pathological features in the tissues of laryngeal carcinoma. The results showed that a total of 25 case-control studies were finally included with 1333 cases of laryngeal cancer and 528 cases of controls. The difference in the expression of Survivin between the two groups was statistically significant [OR=18.34, 95% CI (11.82, 28.47), P<0.00001]. The difference in the expression of Survivin between laryngeal carcinoma patients with lymph node metastasis or not was statistically significant [OR=0.25, 95% CI (0.17, 0.37), P<0.00001]. The expression of Survivin in clinical I-II stage group was significantly lower than in the clinical stage III-IV group [OR=0.24, 95% CI (0.18, 0.32), P<0.00001]. The expression of Survivin in patients with low/medium differentiation was significantly lower than that in those with high differentiation [OR=0.33, 95% CI (0.26, 0.43), P<0.00001]. The difference in the expression of Survivin among different T stages of laryngeal carcinoma was statistically significant [OR=0.35, 95% CI (0.21, 0.58), P<0.00001]. In conclusion, Survivin may play an important role in the occurrence and development of laryngeal carcinoma, and its high expression is related to the poor prognosis of patients with laryngeal cancer.
为了给中国喉癌治疗与预后的循证医学提供依据，本荟萃分析通过电子检索中国发表的关于喉癌组织中Survivin表达及其与临床病理特征相关性的病例对照研究。结果显示，最终纳入25项病例对照研究，共1333例喉癌病例和528例对照。两组间Survivin表达差异具有统计学意义[OR=18.34，95%CI(11.82, 28.47)，P<0.00001]。有或无淋巴结转移的喉癌患者间Survivin表达差异具有统计学意义[OR=0.25，95%CI(0.17, 0.37)，P<0.00001]。临床I-II期组Survivin表达显著低于临床III-IV期组[OR=0.24，95%CI(0.18, 0.32)，P<0.00001]。低/中分化患者Survivin表达显著低于高分化患者[OR=0.33，95%CI(0.26, 0.43)，P<0.00001]。喉癌不同T分期间Survivin表达差异具有统计学意义[OR=0.35，95%CI(0.21, 0.58)，P<0.00001]。总之，Survivin可能在喉癌发生发展中起重要作用，其高表达与喉癌患者预后不良相关。
